Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 09:00 ET | Source: BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation...
October 24, 2025 12:30 ET | Source: BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, a clinical-stage biopharmaceutical company focused on the design and development of next-generation...
October 14, 2025 07:00 ET | Source: BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics Announces Upcoming Poster Presentation on Phase 1/2 SOLARA Trial of BH-30643, a First-in-class, Macrocyclic OMNI-EGFR™ Inhibitor, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer,...
August 22, 2025 08:00 ET | Source: BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer

BlossomHill Therapeutics, Inc. today announced the first patient dosed in the expansion cohorts of the SOLARA trial, the first-in-human trial of BH-30643.
May 09, 2025 08:00 ET | Source: BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President

SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines...
March 03, 2021 16:01 ET | Source: BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics Closes $71M Series A Financing

SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that the company raised $71...